Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011:2011:843763.
doi: 10.1155/2011/843763. Epub 2011 Apr 5.

Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis

Affiliations
Review

Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis

Alan P Knutsen et al. Clin Dev Immunol. 2011.

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a Th2 hypersensitivity lung disease in response to Aspergillus fumigatus that affects asthmatic and cystic fibrosis (CF) patients. Sensitization to A. fumigatus is common in both atopic asthmatic and CF patients, yet only 1-2% of asthmatic and 7-9% of CF patients develop ABPA. ABPA is characterized by wheezing and pulmonary infiltrates which may lead to pulmonary fibrosis and/or bronchiectasis. The inflammatory response is characterized by Th2 responses to Aspergillus allergens, increased serum IgE and eosinophilia. A number of genetic risks have recently been identified in the development of ABPA. These include HLA-DR and HLA-DQ, IL-4 receptor alpha chain (IL-4RA) polymorphisms, IL-10-1082GA promoter polymorphisms, surfactant protein A2 (SP-A2) polymorphisms, and cystic fibrosis transmembrane conductance regulator gene (CFTR) mutations. The studies indicate that ABPA patients are genetically at risk to develop skewed and heightened Th2 responses to A. fumigatus antigens. These genetic risk studies and their consequences of elevated biologic markers may aid in identifying asthmatic and CF patients who are at risk to the development of ABPA. Furthermore, these studies suggest that immune modulation with medications such as anti-IgE, anti-IL-4 and/or IL-13 monoclonal antibodies may be helpful in the treatment of ABPA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Proposed immunopathogenesis of ABPA. In the pathogenesis of ABPA, A. fumigatus proteases have a direct effect on bronchial epithelia causing epithelial cell damage with subsequent stimulation of cytokines and chemokines. Aspergillus proteins are processed via HLA-DR2/DR5 bearing dendritic cells that skew the Th0 response to a Th2 response. Th2 cytokines stimulate IgE synthesis and eosinophil activation. This leads to an eosinophilic inflammatory in the bronchial airways. Abbreviations: Af: Aspergillus fumigates, Asp fx: Aspergillus fumigatus proteins, APC: antigen presenting cell, MBP: major basic protein, ECP: eosinophil cationic protein, EDN: eosinophil derived neurotoxin, VLA: very late activation antigen, VCAM: vascular cell adhesion molecule, CxCR and CCR: chemokines receptors, MCO: monocyte chemotactic protein, sCD23: soluble CD23, cyst-LT: cysteinyl leukotriene.

References

    1. Hinson K, Moon A, Plummer N. Broncho-pulmonary aspergillosis. Thorax. 1952;7:317–333. - PMC - PubMed
    1. Patterson R, Golbert TM. Hypersensitivity disease of the lung. University of Michigan Medical Center journal. 1968;34(1):8–11. - PubMed
    1. Slavin RG, Stanczyk DJ, Lonigro AJ, Broun GO. Allergic bronchopulmonary aspergillosis-A north American rarity. Clinical and immunologic characteristics. The American Journal of Medicine. 1969;47(2):306–313. - PubMed
    1. Knutsen AP, Mueller KR, Levine AD, Chouhan B, Hutcheson PS, Slavin RG. Asp f I CD4+ T(H2)-like T-cell lines in allergic bronchopulmonary aspergillosis. Journal of Allergy and Clinical Immunology. 1994;94(2):215–221. - PubMed
    1. Greenberger PA, Patterson R. Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. Journal of Allergy and Clinical Immunology. 1988;81(4):646–650. - PubMed

MeSH terms